TNF and inflammatory bowel disease: IBD pharmacotherapy has been revolutionized by the use of biological drugs, including monoclonal antibodies against TNF-α (infliximab, adalimumab, golimumab), integrins (vedolizumab and natalizumab), IL-12 and IL-23 (ustekinumab).